{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T11:40:12Z","timestamp":1725104412024},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,22]]},"DOI":"10.7759\/cureus.15174","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T16:24:21Z","timestamp":1621700661000},"source":"Crossref","is-referenced-by-count":3,"title":["Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Shaunak K","family":"Pandya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Ulrickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JiaXi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Willen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arati","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman Y","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, et al.. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001, 2:261-8. 10.1038\/85330","journal-title":"Nat Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir ME","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008, 26:677-704. 10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24112071","article-title":"Development of the inhibitors that target the PD-1\/PD-L1 interaction-a brief look at progress on small molecules, peptides and macrocycles","volume":"24","author":"Guzik K","year":"2019","unstructured":"Guzik K, Tomala M, Muszak D, et al.. Development of the inhibitors that target the PD-1\/PD-L1 interaction-a brief look at progress on small molecules, peptides and macrocycles. Molecules. 2019, 24:2071. 10.3390\/molecules24112071","journal-title":"Molecules"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious D","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017, 82:128-36. 10.1016\/j.ejca.2017.05.041","journal-title":"Eur J Cancer"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P4.2-007","article-title":"Pembrolizumab-induced myasthenia gravis (P4.2-007)","volume":"92","author":"Algaeed M","year":"2019","unstructured":"Algaeed M, Mukharesh L, Heinzelmann M, Kaminski HJ. Pembrolizumab-induced myasthenia gravis (P4.2-007). Neurology. 2019, 92:15.","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12128","article-title":"Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer","volume":"3","author":"Todo M","year":"2020","unstructured":"Todo M, Kaneko G, Shirotake S, et al.. Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer. IJU Case Rep. 2020, 3:17-20. 10.1002\/iju5.12128","journal-title":"IJU Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A6542","article-title":"Myasthenia gravis: a rare immune related adverse event of pembrolizumab","author":"Kankanala VL","year":"2019","unstructured":"Kankanala VL, Kotecha N. Myasthenia gravis: a rare immune related adverse event of pembrolizumab. Critical care case reports: hematology, oncology, rheumatology and immunology. 2019, 10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A6542","journal-title":"Critical care case reports: hematology, oncology, rheumatology and immunology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March KL","year":"2018","unstructured":"March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract. 2018, 24:146-9. 10.1177\/1078155216687389","journal-title":"J Oncol Pharm Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9192","article-title":"Pembrolizumab-induced ocular myasthenic crisis","volume":"12","author":"Lorenzo CJ","year":"2020","unstructured":"Lorenzo CJ, Fitzpatrick H, Campdesuner V, George J, Lattanzio N. Pembrolizumab-induced ocular myasthenic crisis. Cureus. 2020, 12:e9192. 10.7759\/cureus.9192","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/874680","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth A","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012, 2012:874680. 10.1155\/2012\/874680","journal-title":"Autoimmune Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer N","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, et al.. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016, 263:1473-94. 10.1007\/s00415-016-8045-z","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis C","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol Clin. 2018, 36:311-37. 10.1016\/j.ncl.2018.01.011","journal-title":"Neurol Clin"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof LC","year":"2010","unstructured":"Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010, 85:838-54. 10.4065\/mcp.2010.0099","journal-title":"Mayo Clin Proc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities associated with checkpoint inhibitors-an overview","volume":"58","author":"Spiers L","year":"2019","unstructured":"Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford). 2019, 58:vii7-vii16. 10.1093\/rheumatology\/kez418","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.10.6430","article-title":"Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis","volume":"166","author":"Wang HB","year":"2001","unstructured":"Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol. 2001, 166:6430-6. 10.4049\/jimmunol.166.10.6430","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab N","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018, 168:121-30. 10.7326\/M17-2073","journal-title":"Ann Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/59407-pembrolizumab-associated-seronegative-myasthenia-gravis-in-a-patient-with-metastatic-renal-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T10:56:59Z","timestamp":1725101819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/59407-pembrolizumab-associated-seronegative-myasthenia-gravis-in-a-patient-with-metastatic-renal-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.15174","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2021,5,22]]}}}